Clinical trials: Second-Line
Recurrent/Metastatic Gastric Cancer
Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer
This is a Phase 1b/2 study to identify the recommended dose of M7824 for further study with weekly paclitaxel, and to assess the safety and clinical efficacy of this combined treatment in advanced gastric cancer after first line…
- Trial name
- NCT04835896
- Testing
- M7824+paclitaxel
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University
Graft Vs Host Disease
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
- Trial name
- NCT00035880
- Testing
- ABX-CBL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Abgenix
HIV-2 Infection
RESIST-2: 2nd-line ART for HIV-2 Infection
Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.
- Trial name
- RESIST-2 (NCT03394196)
- Testing
- HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Where
- 2 sites in Senegal
- Volunteers
- 152 people
- Sponsor
- University of Washington
Multiple Myeloma
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
This is an open-label, phase 1 study to assess the safety, pharmacodynamics, and anti-myeloma effects of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03549442
- Testing
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Non Small Cell Lung Cancer Metastatic
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement.
- Trial name
- ORAKLE (NCT04111705)
- Testing
- Lorlatinib
- Where
- 32 sites in France
- Volunteers
- 23 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00984542
- Testing
- bendamustine hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Hepatocellular, Secondary
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.
- Trial name
- NCT02716766
- Testing
- Sorafenib, Capecitabine, Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 46 people
- Sponsor
- The University of Hong Kong
Solid Tumor
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
This is a multi-center, phase Il trial to evaluate the efficacy and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs in the treatment of advanced second-line and above solid tumors.
- Trial name
- NCT06537505
- Testing
- Adebrelimab, Apatinib, microwave ablation
- Volunteers
- 60 people
- Sponsor
- Beidahuang Industry Group General Hospital
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line…
- Trial name
- NCT07518602
- Testing
- Chidamide, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Cholestasis, Progressive Familial Intrahepatic 3
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor prognosis (overall survival < 3% at 5 years).
- Trial name
- CHOLANGIOSIR (NCT01383746)
- Testing
- Yttrium microsphere injection
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neoplasms, Gastrointestinal Tract
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
EGF104578 is two-part study (Pilot part/Randomized part).Pilot part is designed to find the optimal (best) doses of lapatinib and paclitaxel when given together,Randomized part is designed to evaluate the overall survival in…
- Trial name
- NCT00486954
- Testing
- Lapatinib, Paclitaxel
- Where
- 17 sites in China, Japan and 2 more
- Volunteers
- 273 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Non-Squamous Non-Small Cell Lung Cancer
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line…
- Trial name
- NCT01659970
- Where
- 110 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer
- Trial name
- NCT04653480
- Testing
- Surufatinib, Toripalimab, chemotherapy
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University
Biliary Tract Carcinoma
Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma
To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.
- Trial name
- NCT06430827
- Testing
- irinotecan hydrochloride liposome injection, Capecitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ba Yi
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00365053
- Testing
- belinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer
PD-1 antibody has been approved as second line therapy for driven mutation negative non-small cell lung cancer, but overall response rate is only between 15-20%.
- Trial name
- NCT03958097
- Testing
- NK cell and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Colorectal Cancer Metastatic
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The aim of this clinical trial is to find out whether Regorafenib and Sintilimab in combination with electroacupuncture works in treating participants with microsatellite stable (MSS) advanced colorectal cancer who have failed…
- Trial name
- NCT06456515
- Testing
- Regorafenib and Sintilimab in combination with electroacupuncture
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First People's Hospital of Changzhou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.